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Abstract
Objective: Granzyme B (GrB) is a pro-apoptotic serine protease that contributes to immune-mediated target cell apoptosis.
However, during inflammation, GrB accumulates in the extracellular space, retains its activity, and is capable of cleaving
extracellular matrix (ECM) proteins. Recent studies have implicated a pathogenic extracellular role for GrB in cardiovascular
disease, yet the pathophysiological consequences of extracellular GrB activity remain largely unknown. The objective of this
study was to identify proteoglycan (PG) substrates of GrB and examine the ability of GrB to release PG-sequestered TGF-b1
into the extracellular milieu.
Methods/Results: Three extracellular GrB PG substrates were identified; decorin, biglycan and betaglycan. As all of these
PGs sequester active TGF-b1, cytokine release assays were conducted to establish if GrB-mediated PG cleavage induced TGF-
b1 release. Our data confirmed that GrB liberated TGF-b1 from all three substrates as well as from endogenous ECM and this
process was inhibited by the GrB inhibitor 3,4-dichloroisocoumarin. The released TGF-b1 retained its activity as indicated by
the induction of SMAD-3 phosphorylation in human coronary artery smooth muscle cells.
Conclusion: In addition to contributing to ECM degradation and the loss of tissue structural integrity in vivo, increased
extracellular GrB activity is also capable of inducing the release of active TGF-b1 from PGs.
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Introduction
Granzyme B (GrB) is a pro-apoptotic serine protease initially
characterized in the granules of CTLs and NK cells. GrB is
released towards target cells along with the pore-forming protein,
perforin, resulting in its perforin-dependent internalization into the
cytoplasm and subsequent induction of apoptosis [1,2]. However,
while once thought to be primarily involved in CTL/NK cell-
mediated apoptosis, it is now recognized that GrB can be
expressed by other inflammatory cells (eg. macrophages, mast
cells, dendritic cells, basophils) as well as non-immune cells (eg.
chondrocytes, smooth muscle cells, keratinocytes, reviewed in [3]).
As non-immune cells do not possess cytotoxic granules, rarely
express perforin and do not readily form immunological synapses
with target cells, GrB is secreted from these cells into the
extracellular milieu. Indeed mounting evidence suggests that GrB
exhibits non-apoptotic, perforin-independent roles involving
matrix degradation in the pathogenesis of chronic inflammatory
diseases (Summarized in [2,3]).
Extracellular levels of GrB are elevated in the bodily fluids in
chronic inflammatory diseases such as atherosclerosis, COPD
and rheumatoid arthritis [2,4,5,6,7]. As further direct support
for an extracellular role for GrB in disease, we have recently
shown that GrB contributes to murine abdominal aortic
aneurysm (AAA) pathogenesis through the cleavage of extracel-
lular matrix (ECM) proteins such as fibrillin-1 and decorin [8,9].
We have also shown that GrB-cleavage of decorin contributes to
collagen disorganization and frailty in the skin of aging mice
[10]. In the latter study, GrB deficiency attenuated collagen
disorganization, reduction of thick collagen bundles and skin
thinning.
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e33163Although extracellular GrB accumulation in chronic inflamma-
tion is well-established (Reviewed in [2]), the consequences of
active GrB accumulation in the extracellular milieu requires
further investigation. In addition to fibrillin-1, known extracellular
GrB substrates include aggrecan, von willebrand factor, plasmin,
fibronectin, laminin, vitronectin, and neuronal glutamate receptor
[8,11,12,13,14,15,16], however the known pathophysiological
implications of ECM cleavage are limited.
The ECM is a fundamental component of tissue, providing a
structural framework for stability and elasticity. It also provides
an essential scaffold for cell survival, acts as a molecular filter, and
influences cell signaling and phenotype. In particular relevance to
the present study, the ECM acts as a reservoir for growth factors
and cytokines by influencing their storage, location, concentra-
tion, activation, synthesis and degradation [17]. Extracellular
proteases such as the matrix metalloproteases (MMPs) act in
regulating growth factor bioavailability by cleaving ECM and
releasing sequestered cytokines, as well as by activating latent
growth factors [17,18]. One such family of growth factors is
TGF-b, which is involved in numerous processes including
differentiation, migration and ECM synthesis [19,20]. TGF-b is
normally secreted as a latent protein but both the active and
inactive forms of TGF-b are bound and sequestered by ECM,
albeit by different mechanisms. For example, fibrillin-1 sequesters
inactive TGF-b by interacting with the latent TGF-b binding
protein (LTBP) while active TGF-b can bind directly to the ECM
proteoglycans (PGs) decorin, biglycan and soluble betaglycan
[17,21,22,23].
Decorin and biglycan are members of the small leucine rich PG
family and are involved in the sequestration of active TGF-b and
in collagen fibre spacing [23,24,25]. Betaglycan, also known as
TGF-b receptor III, is a PG receptor involved in TGF-b signaling.
Its extracellular domain acts as a soluble receptor following
cleavage by membrane type-matrix metalloproteinase (MT-
MMP1), in a process known as ectodomain shedding [26,27].
This soluble betaglycan resides in the ECM and functions in TGF-
b sequestration [22,28].
In the present manuscript we demonstrate that GrB cleaves
decorin, biglycan and betaglycan and identify sites of proteolysis.
We show that the released TGF-b1 is active and induces the
phosphorylation of SMAD-3 in human coronary artery smooth
muscle cells (HCASMCs).
Materials and Methods
Proteoglycan cleavage assays
The recombinant human PGs, decorin (full length and
glycosylated; 1–360 a.a., 0.5 ug, Abnova, Walnut, CA), biglycan
(partial protein and glycosylated; 38–368 a.a., 1.5–5 mg, R&D
Systems Minneapolis, MN) and betaglycan (partial protein and
glycosylated; 21–781 a.a., 2.5–5 mg, R&D Systems) were incubat-
ed at room temperature for 24 h with 25–500 nM purified human
GrB (Axxora, San Diego, CA). Reactions were carried out in
50 mM Tris buffer, pH 7.4. For inhibitor studies, GrB was
incubated in the presence or absence of 200 mM of the serine
protease inhibitor 3,4-dichloroisocoumarin (DCI; Santa Cruz
Biotechnology Inc, Santa Cruz, CA) or inhibitor solvent control,
dimethyl sulfoxide (DMSO; Sigma-Aldrich, St Louis, MO) for 4 h
or 24 h. After incubation, proteins were denatured, separated on a
10% SDS-polyacrylamide gel and transferred to a nitrocellulose
membrane. Ponceau stain (Fisher Scientific, Waltham, MA) was
used to detect cleavage fragments.
Cleavage assays on SMC-derived ECM
HCASMC (Clonetics/Lonza, Walkersville, MD), passages 3–7
were seeded in 6 well plates and once confluent, were incubated
for 5 days in starvation media (smooth muscle growth medium
(SMGM) +0.2% FBS) for adequate ECM synthesis. After
incubation, cells were washed with PBS and incubated with
0.25 M ammonium hydroxide for 20 min, to remove cells but
leave the ECM intact. The ECM was washed with water and
incubated with PBS, GrB, GrB+DCI or GrB+DMSO for 24 h.
Cleavage fragments were collected in the supernatant. ECM
cleavage was detected by western blot for decorin or biglycan
(primary antibodies from R&D Systems).
N-terminal sequencing
For Edman degradation, 2–5 mg/lane of biglycan and betagly-
can were incubated with 100–500 nM GrB for 24 h. Once run on
a gel and transferred to a PVDF membrane, cleavage fragments
were identified by Ponceau staining. The stain was removed by
washes with distilled water and the membrane was dried and
analyzed at the Advanced Protein Technology Center at the
Hospital for Sick Kids (Toronto, ON).
Michaelis-Menten kinetics
For Michaelis-Menten kinetics, 0.05–4 mM of decorin (in
50 mM Tris, pH 7.4), biglycan or betaglycan (in PBS, pH 7.4)
was incubated with 100 nM GrB for 2.5 h at 37C. Reactions were
stopped with SDS-PAGE loading buffer, run on an 8% gel and
detected with G-250 Biosafe Coomassie Stain (Bio-Rad, Hercules
CA). Proteoglycan cleavage was quantified by appearance of
product for biglycan and betaglycan and loss of substrate for
decorin. Enzyme kinetics calculations were carried out with
GraphPad Prism software using linear regression curves for
kinetics analysis.
TGF-b1 release assays
TGF-b1 release assays were carried out using a method similar
to that previously described for the assessment of MMP-induced
TGF-b1 release from ECM [18]. Briefly, decorin, biglycan and
betaglycan (15 mg/mL) were coated onto 48 well tissue culture
plastic plates and allowed to incubate overnight at 4uC in PBS,
pH 7.4. After blocking with 1% bovine serum albumin, 20 ng of
active TGF-b1/well (Peprotech Inc, Rocky Hill, NJ) was added in
dPBS containing calcium and magnesium (Invitrogen, Carlsbad,
CA) for 5 h at RT. GrB, with or without DCI, was incubated on
the wells and after 24 h, supernatants were removed, denatured,
and run on a 15% SDS-PAGE gel. Nitrocellulose membranes
were probed using a rat anti-human TGF-b1 antibody (BD
Biosciences, Franklin Lakes, NJ) and IRDyeH 800 conjugated
affinity purified anti-rat IgG (Rockland Inc, Gilbertsville, PA).
Bands were imaged using the Odyssey Infrared Imaging System
(LI-COR Biotechnology, Lincoln, NE).
For TGF-b1 release from endogenous ECM, SMC-derived
ECM was isolated as described above for the SMC-derived ECM
cleavage assays. ECM was blocked with 1% BSA and incubated
with 0.6 ng/ul TGF-b1 for 3 h at RT. Unbound TGF-b1 was
washed away with PBS and GrB groups were incubated on the
wells for 24 h. Supernatants, containing released TGF-b1, were
run on a SDS-PAGE gel as described above.
TGF-b1 bioavailability assays
For bioavailability assays, HCASMCs were seeded in 6 well
plates in SmGM +5% fetal bovine serum (FBS, Invitrogen) and
grown to confluence. At this time, cells were quiesced by serum
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(as described above) at 5 ng/ml TGF-b1 positive control were
added to the cells for 20 h. Cell lysates were assessed by SDS-
PAGE/Western blotting for phosphorylated-SMAD-3 (p-SMAD3;
Epitomics, Burlingame, CA) total SMAD-2/3 (t-SMAD-2/3; BD
Biosciences) and the loading controls b-actin (Sigma-Aldrich) or b-
tubulin (Millipore, Billerica, MA). Secondary IRDyeH 800
conjugated antibodies (Rockland Inc) were utilized and imaged
with the Odyssey Infrared Imaging System (LI-COR Biotechnol-
ogy, Lincoln, Nebraska). Densitometric analysis was conducted on
the Odyssey Infrared Imaging System and displayed graphically
by p-SMAD-3/total-SMAD-3.
Statistics
For densitometric analysis, a one way analysis of variance
(ANOVA) with a Dunnett’s post test was carried out and
significance was determined at P,0.05.
Results
GrB cleaves decorin, biglycan and betaglycan
Incubation of decorin, biglycan and betaglycan with GrB
resulted in the concentration-dependent generation of multiple
cleavage fragments (Fig. 1a–c). Full length decorin (,65 kDa) and
4 decorin cleavage fragments at ,50 kDa and ,30 kDa, were
evident following GrB incubation. Biglycan was identified at
,40 kDa, with cleavage fragments evident at ,30 kDa and
20 kDa, while incubation of recombinant soluble betaglycan
(,100 kDa) with GrB resulted in multiple cleavage fragments at
,60 kDa and 40 kDa. As all of these substrates are PGs and
contain glycosaminoglycan (GAG) chains, the apparent MW of
the full length proteins and fragments may not be accurate, as
glycosylation can alter movement through the gel. As such, several
of the proteins and protein fragments are observed as a smear as
opposed to a condensed band.
To confirm that decorin, biglycan and betaglycan proteolysis
was mediated by GrB, DCI was included in reactions for 4 h or
24 h (Fig. 2a–c). Higher concentrations of PG substrates and GrB
were utilized in this assay for favorable detection of cleavage
fragments. DCI effectively inhibited decorin, biglycan and
betaglycan cleavage at both time points while the vehicle control
(DMSO) had no effect (Fig. 2a–c).
To verify these PGs are indeed GrB substrates in endogenous
ECM, we repeated the cleavage assay with smooth muscle cell-
derived ECM. As shown in Fig. 3, decorin and biglycan were
indeed cleaved by GrB when associated with an endogenous
ECM. Cleavage fragments for both proteins were apparent in the
supernatant at around ,32 kDa, the same cleavage fragment sizes
seen in recombinant protein assays.
GrB cleavage site identification
GrB cleavage sites were characterized in biglycan and
betaglycan by Edman degradation (Fig. 2b–c). N-terminal
sequence results for decorin were unable to be obtained due to
low fragment yields, despite multiple trials. In biglycan, the
cleavage site was identified at Ile-Ser-Pro-Asp
91Thr-Thr-Leu-Leu-
Asp, with a P1 residue of Asp (Fig. 2b). Interestingly, despite
sequencing 6 unique bands for betaglycan, only one unique
cleavage site was characterized, Asp-Glu-Gly-Asp
558Ala-Ser-Leu-
Phe-Thr, near the c-terminus of the protein (Fig. 2c). The n-
terminal sequence results of betaglycan fragments labeled by ‘1’
corresponded to the n-terminus of the protein and the n-terminal
sequence of fragments labeled with ‘2’ corresponded to the
cleavage site (Fig. 2c).
Michaelis-Menten kinetics
To determine if the cleavage of decorin, biglycan and
betaglycan occurs at physiologically relevant rates, Michaelis-
Menten kinetics was carried out on Commassie stained gels after
2 h incubation at 37C. Kcat/Km ratios for biglycan:
1.7610
3 M
21 s
21, betaglycan: 5.89610
3 M
21 s
21 and decorin:
1.0610
3 M
21 s
21.
GrB-dependent cleavage of biglycan, decorin and
betaglycan results in the release of active TGF-b1
As decorin, biglycan and betaglycan sequester active TGF-b1
[22,23], TGF-b1 release assays were performed to determine if
GrB-mediated cleavage of these proteins resulted in active TGF-
b1 release (Fig. 4a). Following 24 h of incubation, minimal TGF-
b1 had dissociated from the plate in the absence of GrB,
Figure 1. GrB-mediated cleavage of decorin, biglycan and
betaglycan. Increasing concentrations of GrB (25, 50, 100 and 200 nM)
were incubated with decorin (a), biglycan (b), and betaglycan (c) for
24 h at RT. * denotes full length protein, arrows indicate cleavage
fragments and ‘ indicates GrB.
doi:10.1371/journal.pone.0033163.g001
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out the incubation time. After 24 h of GrB treatment, TGF-b1
was released into the supernatants, from all three PGs. This release
was inhibited by DCI, suggesting the process was dependent on
active GrB. TGF-b1 release was observed at GrB levels as low as
25 nM (Unpublished observations).
To confirm GrB can also release TGF-b from a heterogenous,
endogenous ECM, SMC-derived ECM was utilized. However, in
this closed in vitro setting TGF-b is present only as a latent
complex, most likely due to a lack of extracellular activators in the
culture system (Fig. 4b). As decorin, biglycan and betaglycan bind
and sequester active TGF-b only, recombinant active TGF-b1 was
supplemented on isolated ECM prior to GrB incubation. Upon
GrB treatment, TGF-b1 was released from the ECM, while DCI
prevented release (Fig. 4c). This suggests that GrB can release
recombinant TGF-b1 from a native, heterogeneous ECM, in
addition to recombinant PG matrices.
TGF-b1 released by GrB remains active and induces
SMAD signaling in smooth muscle cells
To determine that the TGF-b1 released by GrB remained
active and was not bound to an inhibitory fragment, supernatants
from the betaglycan release assay were incubated on HCASMC
for 20 min (Fig. 5). TGF-b signaling was examined through the
phosphorylation and activation of SMAD-3. HCASMC respond-
ed well to 5 ng/ml TGF-b1, with SMAD-3 phosphorylation
observed at 20 min (P,0.05). The TGF-b1 released from
betaglycan by GrB induced SMAD-3 signaling, confirming that
it remained active (p,0.05). Total SMAD-3 levels also did not
change.
Figure 2. GrB-mediated PG cleavage is inhibited by DCI and cleavage site identification. GrB was incubated with decorin (a), biglycan (b)
and betaglycan (c), +/2 DCI and the solvent control DMSO, for 4 h and 24 h. Cleavage sites in biglycan and betaglycan were identified by N-terminal
Edman degradation. * denotes full length protein, arrows indicate cleavage fragments, and cleavage sites are displayed on the right.
doi:10.1371/journal.pone.0033163.g002
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Although GrB has been primarily studied in the context of its
pro-apoptotic role in cytotoxic lymphocyte-mediated killing,
several lines of evidence now imply an alternative, perforin-
independent extracellular role for this protease in multiple chronic
inflammatory diseases (Reviewed in [2]). In this study, we identify
three novel extracellular substrates of GrB; decorin, biglycan and
betaglycan. Furthermore we demonstrate that upon cleavage of
these PGs by GrB, active TGF-b1 is released.
Approximately one third of GrB is released non-specifically into
the extracellular milieu during immune cell engagement/degran-
ulation and cytotoxic lymphocytes constitutively release GrB in the
absence of target cell engagement [29,30]. In further support of
the biological relevance of non-specific release, the GrB released
into the extracellular milieu during NK killing assays is sufficient to
process IL-1a into a fragment with increased pro-inflammatory
potential [31]. As such, even in cell culture studies there is
sufficient leakage of GrB outside of cells to promote a biological
response. Additionally, under certain conditions, non-inflamma-
tory cell types (eg. Keratinocytes, chondrocytes, pneumocytes) can
express and secrete GrB (reviewed in [3]). As many of these cell
types do not express perforin or form immunological synapses, an
extracellular role for GrB in pathogenesis is plausible. Indeed, in
multiple chronic inflammatory conditions, GrB accumulates in
extracellular fluids including plasma, cerebral spinal fluid, synovial
fluid and bronchoalveolar lavage fluid (BALF, Reviewed in [2]). In
addition, IL-1a fragments of similar size to GrB processed
fragments were detected in BALF from patients with cystic
fibrosis, chronic obstructive pulmonary disease and bronchiectasis
[31]. Given that GrB is often detectable at levels 10 to 100-fold
higher than normal in such fluids and retains its activity, it is highly
probable that this protease could elicit a biological effect in the
source tissues where its concentration would be expected to be
significantly higher. In direct support of this, we have shown using
both GrB and perforin knockout mice that GrB contributes to
abdominal aortic aneurysm and skin aging through a perforin-
independent mechanism involving ECM cleavage [8,10]
Although the concentration range of GrB in inflamed tissues is
presently unknown, the concentrations of GrB used in this study
are likely to be physiologically relevant in chronic inflammatory
disease. Mean levels of GrB in the plasma and synovial fluid of
rheumatoid arthritis patients have been reported to be as high as
1 ng/ml and 3 ng/ml respectively (compared to ,40 pg/ml in
healthy patients), and similar increases of GrB in bodily fluids have
Figure 3. GrB cleaves native smooth muscle cell-derived
decorin and biglycan. HCASMCs were incubated at confluency for
adequate ECM synthesis. Cells were removed, GrB was incubated with
the ECM and decorin and biglycan cleavage fragments were detected
by western immunoblotting.
doi:10.1371/journal.pone.0033163.g003
Figure 4. GrB-mediated cleavage of decorin, biglycan and betaglycan results in the release of active TGF-b1. Decorin, biglycan and
betaglycan complexed with TGF-b1 were treated with GrB. Supernatants (containing released TGF-b1), were collected and released TGF-b1 was
detected by Western blotting. Results shown are representative western blots from at least 3 separate experiments for each PG (a). As endogenous
SMC-derived ECM only contains latent TGF-b (as shown in (b)), GrB-mediated release from active TGF-b1 supplemented ECM was also examined (c).
doi:10.1371/journal.pone.0033163.g004
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circulating GrB would be expected to be several magnitudes lower
than in source tissues, where GrB is being produced and released
and where ECM cleavage is observed [2].
In this study, PG cleavage was detected at GrB concentrations
as low as 25 nM, however, as the sensitivity of ponceau staining is
relatively low, cleavage of these proteins may also occur at lower
GrB concentrations. In addition to recombinant protein cleavage
assays, we examined biglycan and decorin cleavage from a
heterogeneous matrix synthesized by smooth muscle cells (SMCs).
A ,32 kDa cleavage fragment for both decorin and biglycan was
detected in this assay, which were similar in size to the fragments
derived from the recombinant substrate. As fragments were
detected using monoclonal antibodies that recognize only one
epitope of the proteins, other cleavage fragments were not
detected. Soluble betaglycan was not detectable in ECM in this
in vitro setting, suggesting it is either weakly expressed by SMCs or
rarely shed by these cells in vitro.
GrB may also have affinity for ECM upon release, particularly
in PG-rich ECM as GrB has been previously described to bind
sulfated glycosaminoglycans. During the storage and release of
GrB from cytotoxic granules, GrB binds to the heparan sulfate
GAG chains of the PG serglycin [33]. Additionally, cells with
reduced membrane GAG chain content displayed a decrease in
GrB-mediated cell death, likely due to reduced electrostatic GrB
transfer from serglycin to membrane associated GAG chains, such
as chondroitin sulfate or heparan sulfate [34,35,36]. GrB affinity
for these GAG chains has been proposed to be due to GrB cationic
sites that bind electrostatically to anionic GAGs [35]. As decorin
and biglycan contain chondroitin sulfate GAG chains and
betaglycan contains both chondroitin sulfate and heparin sulfate
chains, it is probable that GrB also exhibits increased affinity for
these ECM PGs, potentially accumulating in PG-rich ECM.
Previously, GrB-mediated cleavage of another extracellular PG,
aggrecan, was described [12] and other unidentified cartilage PGs,
were shown to be cleaved in rheumatoid arthritis [37]. Whether or
not decorin, biglycan or betaglycan were among the PGs cleaved
in this study is not known but in our experience, it does appear
that GrB has a preference for extracellular PG substrates.
In the present study, Michaelis-Menten kinetics was carried out
to examine if GrB-mediated cleavage of these substrates was
physiologically relevant in a biochemical context. In this
environment, rates were lower than that for GrB-mediated
cleavage of aggrecan, suggesting GrB may have a greater affinity
for aggrecan than other proteoglycans [12]. It was also
considerably lower than that determined for decorin cleavage by
MMP 2, 3 and 7 [18]. However, biochemical assessment of in vivo
relevance in an artificial test tube environment obviously has its
limitations with respect to recapitulating other factors and what is
actually occurring the extracellular milieu that is found in vivo. In
Figure 5. TGF-b1 released by GrB is active and induces SMAD-3 activation in HCASMCs. GrB+/2DCI was incubated on betaglycan/TGF-b1
complexes for 24 h. Supernatants (containing released TGF-b1) were added to HCASMC for 20 m and phosphorylated SMAD-2 and SMAD-3 levels
were examined. TGF-b1 released by GrB is active and induces SMAD-3 signalling in HCASMCs (P,0.05). The result shown is representative of at least 5
experiments.
doi:10.1371/journal.pone.0033163.g005
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this rate is likely significant as GrB has a high affinity for PGs
leading to its increased accumulation and cleavage would occur
over a prolonged period of time in areas of extracellular GrB
accumulation, as suggested in previous publications [9,10]. In
addition, several other proteases have been characterized to cleave
substrates as similar rates, and have been determined to be
catalytically efficient [38,39,40,41,42]. Nonetheless, future studies
are necessary to examine GrB-mediated proteoglycan cleavage in
vivo and to identify GrB-derived cleavage fragments in chronic
human disease.
Despite the fact that several extracellular GrB substrates have
been identified, very few of the cleavage sites have been
determined. In this study we define the GrB cleavage sites for
biglycan and betaglycan. GrB residue preferences have been
previously described, and GrB cleavage sites have generally been
characterized with a P1 residue of aspartic acid [43,44]. Less
frequently however, cleavage at non-Asp P1 residues have been
reported. The most commonly characterized alternate P1 residue
is Glu acid but P1 residues of Ser, Asp and Met have also been
shown but are suspected to occur at lower kinetics and may be
nonspecific [45,46]. In addition to its P1 specificity, GrB also has a
preference for P3 residues that are negatively charged and P4
residues that are hydrophobic [45,46]. P3, P2 and P19 tended to
be smaller residues, most likely due to the size restrictions of the
peptide binding pocket [46]. In this study, we show that GrB
cleaved these PG substrates at a P1 residue of Asp (biglycan: D
91,
betaglycan: D
558), consistent with the literature described above.
Biglycan contains a hydrophobic residue at P4 (Ile), betaglycan has
a negative charge at P3 (Glu) and both contained relatively small
resides in the P3, P2, P19 area, reflecting the cleavage site trends
described previously [46].
Interestingly, GrB is the only known extracellular protease
capable of cleaving extracellular substrates at a P1 residue of
aspartic acid. This unique specificity could potentially be used as a
tool to initially screen for potential GrB-derived fragments in
bodily fluids, of these substrates and others. In addition, the acidic
side chain of aspartic acid is key for ionic interactions and
molecular recognition by receptors. This is of particular interest
for fragments containing RGD sequences, which have various
biological activities in cell signaling and disease.
We have recently shown that GDKO mice are protected from
the skin aging and frailty characteristic of aged apoE-KO mice
and that GrB localization corresponds to areas of decorin
degradation in apoE-KO mice [10]. The collagen fiber density
loss evident in apoE-KO mice was not evident in GDKO mice,
suggesting GrB-mediated degradation of decorin may result in
collagen remodeling in aging skin. Importantly with respect to the
present study, these studies support the premise that GrB-
mediated PG cleavage does occur in vivo.
GrB contributes to aortic aneurysm via an extracellular
mechanism involving the cleavage of the microfibrillar protein
fibrillin-1 [8]. In a subsequent study, we demonstrate that
adventitial decorin is reduced in apoE-KO aneurysms at sites
adjacent to thrombi and in areas of injury [9]. GrB-deficiency
and/or inhibition prevented this reduction in decorin leading to a
thickened, healed, adventitia. Whether reduced decorin degrada-
tion leads to increased circumferential strength requires further
elucidation, however, in the latter study a reduced incidence of
rupture in GDKO mice compared to ApoE-KO mice was
observed [8]. Of further interest, elevated GrB [8] and reduced
decorin [47,48] are observed in human aneurysm specimens.
Adventitial collagen is critical for vessel strength/stability and
collagen homeostasis/spacing is regulated by decorin, suggesting
that decorin degradation would exert a negative impact on aortic
wall strength and increase susceptibility to rupture [49].
A reduction in decorin levels has been found in wound healing
models such as keloids, a variant of Ehlers-Danlos syndrome
chronic skin ulcer and in the skin upon ultraviolet light exposure
[50,51,52,53]. Of particular interest, 32 kDa and 45 kDa decorin
fragments were identified in human keloid tissue of similar size to
GrB-derived fragments [51,52].
Decorin, biglycan and betaglycan are known to sequester active
TGF-b [22,23]. Therefore, we asked whether cleavage of these
PGs by GrB could release the growth factor. Matrix metallopro-
teases (MMP) are well characterized in their role in ECM
degradation [54,55] and cytokine/growth factor bioavailability as
MMP-2, -3 and -7 have all been shown to release TGF-b1 from
decorin [18]. To examine if GrB may have a similar effect we
utilized a similar TGF-b1 release assay in our studies [18]. TGF-
b1 was released from all three substrates. In addition, the TGF-b1
released by GrB induced SMAD-3 phosphorylation, confirming
that GrB releases active TGF-b1 and does not alter TGF-b1
activity. As GrB liberates active TGF-b1 from the three most well
described active TGF-b reservoirs, it may be a potent factor in
influencing TGF-b bioavailability. To this end, we are not aware
of another protease that has been described to release TGF-b from
all three of these extracellular proteins. In addition, there are no
confirmed extracellular inhibitors of GrB, as opposed to the
MMPs, which are tightly-regulated extracellular proteases. One
could speculate that GrB may not have an extracellular means of
inhibition, as it appears to accumulate specifically during sustained
inflammation. As such, increased extracellular GrB could lead to
dysregulated TGF-b release and contribute to a multitude of
deleterious effects at the site of injury. However, more work is
necessary to confirm this hypothesis.
TGF-b down-regulates GrB and perforin expression in
cytotoxic T cells [56]. However, the effect of TGF-b on GrB
expression by other cell types is currently unknown. There is
potential for TGF-b to act in a negative feedback loop in human
tissue, whereby an increase in extracellular GrB levels would lead
to an increase in TGF-b bioavailability. This could influence
subsequent GrB expression, perhaps as a safety mechanism in
disease. The effect of GrB-mediated release of TGF-b on
subsequent GrB expression warrants further investigation.
In conclusion, the present knowledge of extracellular GrB
activity in health and disease is in its infancy [57]. In addition to
identifying three novel substrates for GrB, the present study
provides further insight as to how an accumulation of GrB in the
extracellular milieu could negatively impact and/or alter growth
factor sequestration by the ECM.
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